α-Hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance

Diabetes Care

Volumn 39, Issue 6, 2016, Pages 988-995

  Cobb, Jeff ^a   Eckhart, Andrea ^a   Motsinger Reif, Alison ^b   Carr, Bernadette ^c   Groop, Leif ^d   Ferrannini, Ele ^e  

^a METABOLON INC   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c Vhi Healthcare Ltd   (Ireland)

^d LUND UNIVERSITY   (Sweden)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; GLUCOSE; GLYCEROPHOSPHOLIPID; HYDROXYACID; LINOLEOYL GLYCEROPHOSPHOCHOLINE; OLEIC ACID; UNCLASSIFIED DRUG; 2-HYDROXYBUTYRIC ACID; GLUCOSE BLOOD LEVEL; HYDROXYBUTYRIC ACID;

ADULT; AGE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; SEX DIFFERENCE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY;

ADULT; BIOMARKERS; BLOOD GLUCOSE; COHORT STUDIES; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROXYBUTYRATES; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLEIC ACID; PREDIABETIC STATE; PROSPECTIVE STUDIES;

EID: 84971280944     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2752     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
2. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010;33:2355-2359
3. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
4. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299
5. Ferrannini E, Massari M, Nannipieri M, Natali A, Ridaura RL, Gonzales-Villalpando C. Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. Diabetologia 2009; 52:818-824
6. Schöttker B, Raum E, Rothenbacher D, Müller H, Brenner H. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol 2011;26:779-787
7. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 2013;56:1489-1493
8. Rich PA, Shaefer CF, Parkin CG, Edelman SV. Using a quantitative measure of diabetes risk in clinical practice to target and maximize diabetes prevention interventions. Clin Diabetes 2013; 31:82-89
9. Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol 2014;2: 65-75
10. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
11. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639-648
12. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012;8:615
13. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013;62: 1730-1737
14. Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013;62:4270-4276
15. Cobb J, Eckhart A, Perichon R, et al. A novel test for IGT utilizing metabolite markers of glucose tolerance. J Diabetes Sci Technol 2015;9: 69-76
16. Ferrannini E, Natali A, Muscelli E, et al.; RISC Investigators. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 2011;54:1507-1516
17. Sinnott M, Kinsley BT, Jackson AD, et al. Fasting plasma glucose as initial screening for diabetes and prediabetes in Irish adults: The Diabetes Mellitus and Vascular Health Initiative (DMVhi). PLoS One 2015;10:e0122704
18. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sexspecific parental effects. Diabetes 1996;45: 1585-1593
19. Hills SA, Balkau B, Coppack SW, et al.; EGIR-RISC Study Group. The EGIR-RISC Study (the European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 2004;47: 566-570
20. Andersen GS, Thybo T, Cederberg H, et al.; DEXLIFE Consortium. The DEXLIFE study methods: identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals. Diabetes Res Clin Pract 2014;106:383-389
21. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-731
22. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. Available from http://www.R-project.org/. Accessed 2 June 2014
23. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44: 837-845
25. Gall WE, Beebe K, Lawton KA, et al.; RISC Study Group. α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010;5:e10883
26. Laakso M, Zilinskaite J, Hansen T, et al.; EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 2008;51: 502-511
27. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108(Suppl.): 3B-24B
28. Varvel SA, Pottala JV, Thiselton DL, et al. Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTT. BMJ Open Diabetes Res Care 2014;2:e000038
29. Cobb J, Gall W, Adam K-P, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol 2013;7:100-110
30. Plummer DT, Elliott BA, Cooke KB, Wilkinson JH. Organ specificity and lactate-dehydrogenase activity. 1. The relative activities with pyruvate and 2-oxobutyrate of electrophoretically separated fractions. Biochem J 1963;87:416-422
31. Paxton R, Scislowski PWD, Davis EJ, Harris RA. Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism. Biochem J 1986; 234:295-303
32. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond) 2014;11:10
33. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM, Harris RA. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 1999;48:1593-1599
34. Steffen BT, Steffen LM, Zhou X, Ouyang P, Weir NL, Tsai MY. n-3 fatty acids attenuate the risk of diabetes associated with elevated serum nonesterified fatty acids: the multi-ethnic study of atherosclerosis. Diabetes Care 2015;38:575-580
35. Rubio-Aliaga I, de Roos B, Duthie SJ, et al. Metabolomics of prolonged fasting in humans reveals new catabolic markers. Metabolomics 2011;7:375-387
36. Lord RS, Bralley JA. Clinical applications of urinary organic acids. Part I: detoxification markers. Altern Med Rev 2008;13:205-215
37. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr 2011;2: 445-456
38. Lackey DE, Lynch CJ, Olson KC, et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and crossadipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab 2013;304:E1175-E1187
39. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012;15: 606-614